Table 1.

Clinical Researchers of Nivolumab in Neoadjuvant Immunotherapy with NSCLC

Trails	NCT	Primary Outcome Measures	Secondary Outcome Measure	Estimated Enrollment	Stage	Estimated Primary Completion Date
Checkmate816	02998528	EFS, pCR	OS, MPR, TTDM	350	IB(T>4cm)-IIIA	2020/4/8
Checkmate77T	04025879	EFS	OS, pCR, MPR, SAEs, AEs	452	IIA(T>4cm)-IIIB (T3N2)	2023/5/24
ANVIL	02595944	DFS, OS	AEs	903	IB (T≥4cm) -IIIA	2024/7/1
NADIM II	03838159	pCR	-	90	IIIA-IIIB (T3N2)	2022/3/15

Abbreviations: NSCLC, non small cell lung cancers; EFS, event-free survival; OS, overall survival; TTDM, time to death or distant metastases; SAEs, incidence of serious adverse events; AEs, incidence of adverse events; DFS, disease-free survival.